Sepsis and multiorgan dysfuction - Sepsis goes public

09.09.2009 - 12.09.2009 All day

Prof. John Myburgh from Sydney will present the exiting unpublished results from the in-depth analysis of effects of human albumin in sepsis patients that were observed in the context of the SAFE study.

In a second talk, Prof Myburgh, the principal investigator of the CHEST-trial, will delineate the necessity to assess the safety of HES 130/0.4 in critically ill patients.

Prof. Massimo Antonelli from Rome will present the interesting data from a multicenter study on the use of Polymyxin B Hemoperfusion in abdominal septic shock.